Search results
Feb 19, 2024 · Divalproex sodium. Generic name: divalproex sodium [ dye-val-PRO-ex ] Brand names: Depakote, Depakote ER, Depakote Sprinkles. Dosage forms: oral delayed release capsule (125 mg), oral delayed release tablet (125 mg; 250 mg; 500 mg), ... show all 3 dosage forms. Drug class: Fatty acid derivative anticonvulsants.
What Is Divalproex Sodium and How Does It Work? Divalproex sodium is a stable coordination compound comprised of sodium valproate and valproic acid used to treat manic episodes associated with bipolar disorder, epilepsy, and migraine headaches.
Indicated for treatment of manic episodes associated with bipolar disorder. Depakote initial dose: 750 mg/day PO in divided doses. Depakote ER initial dose: 25 mg/kg PO once daily Increase as...
Purpose: A novel once-daily divalproex-extended release (ER) dose formulation has been developed; this formulation prolongs the therapeutic serum levels of the drug, compared with the twice-daily conventional divalproex-delayed release (DR) formulation.
Dec 12, 2021 · In our study, divalproex-extended release (VPA-ER) and divalproex-delayed release (VPA-DR) will be defined as all extended-release and delayed-release formulations of VPA, respectively. In ER formulations, the dosing interval is usually extended to minimize the dosing frequency.
Apr 4, 2022 · It has been reported that extended-release divalproex sodium can reduce the incidence of AEs associated with divalproex sodium (Stoner et al., 2004), and another retrospective study also reported fewer AEs in patients taking the divalproex ER formulation (Minirth and Neal, 2005).
Mar 19, 2024 · Divalproex sodium is the stable, coordinated compound of sodium valproate and VPA. Due to its distinctive extensive spectrum of anticonvulsant effects, divalproex sodium is used to manage a wide range of seizure disorders, such as myoclonic epilepsy syndromes, absence epilepsy, generalized convulsions, partial seizures, and status epilepticus.
Objective: The efficacy and safety of dival-proex sodium extended release (divalproex ER) were evaluated in patients hospitalized for acute mania associated with bipolar I disorder, manic or mixed type (DSM-IV-TR criteria).
Results: Patients treated with divalproex sodium compared with patients treated with valproic acid were less likely to have gastrointestinal side effects (14.7% vs. 28.7%, p = .003), specifically anorexia (6.0% vs. 14.7%, p = .012), nausea or vomiting (6.7% vs. 16.7%, p = .007), and dyspepsia (11.3% vs. 22.0%, p = .013).
Jul 23, 2024 · The efficacy of divalproex sodium extended-release tablets is based in part on studies of divalproex sodium delayed-release tablets in this indication, and was confirmed in a 3-week trial with patients meeting DSM-IV TR criteria for bipolar I disorder, manic or mixed type, who were hospitalized for acute mania [see Clinical Studies ( 14.1)].
